Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single centre, open-label, randomised clinical trial to investigate Meningococcal serogroup A, C, W-135 and Y saccharide specific B cell response to a primary and a booster dose of the Meningococcal ACWY conjugate vaccine and to a primary dose of the ACWY polysaccharide vaccine followed by a booster dose of the Meningococcal ACWY conjugate vaccine administered to adult volunteers.

Trial Profile

A single centre, open-label, randomised clinical trial to investigate Meningococcal serogroup A, C, W-135 and Y saccharide specific B cell response to a primary and a booster dose of the Meningococcal ACWY conjugate vaccine and to a primary dose of the ACWY polysaccharide vaccine followed by a booster dose of the Meningococcal ACWY conjugate vaccine administered to adult volunteers.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 21 Jun 2012 Actual initiation date changed from 1 Jun 2009 to 27 Apr 2009 and official title amended as reported by European Clinical Trials Database.
    • 23 Oct 2011 Results assessing memory B-cell levels presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
    • 27 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top